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Using biomarkers and early prophylactic 
treatment to prevent cardiotoxicity in 
cancer patients on chemotherapy
goal for both cardiologists and oncologists. The main strategy to 
prevent clinical cardiotoxicity is early detection and the initiation of 
prompt prophylactic therapy. 
EARLY DETECTION OF CARDIOTOXICITY
Current approach
Periodic assessment for LVEF is the most widely used non-invasive 
method for detecting cardiotoxicity LVEF either via echocardi-
ography or multigated acquisition scanning. Although several 
available guidelines exist none specify how often, by what means or 
how long cardiac function should be monitored during and after 
cancer treatment. The recommendations of these guidelines are 
not consistent and seem to be based on modest evidence.(5) 
Though LVEF is a crude index of cardiac function, it is relatively 
insensitive in detecting anticancer drug-induced cardiotoxicity at an 
early stage. Usually there are compensatory mechanisms in place to 
ensure normal overall function in a patient despite an initial 
reduction in myocardial contractility. As a rule no considerable 
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Anticancer therapy can frequently result in serious side effects on 
specific organs and cardiac toxicity is of considerable concern. 
Once toxicity develops it may compromise the treatment’s clinical 
effectiveness independent of the oncologic prognosis.(1) The most 
frequent - and feared - clinical manifestation of cardiotoxicity is the 
development of left ventricular dysfunction (LVD), that may impact 
on the patient’s survival and quality of life; thus the gain in life 
expectancy due to anticancer therapy might be compromised by 
the risk of increased cardiac mortality. Moreover - even when 
asymptomatic - LVD not only negatively influences patients’ 
cardiologic outcomes - it also seriously limits their therapeutic 
opportunities when adjunctive oncologic therapy for cancer relapse 
or persistence is required. The presence of LVD restricts the choice 
of possible oncologic treatments to the less aggressive and, 
consequently, less effective options.
Over the last years, the weight of the cardiac toxicity of anticancer 
treatment has markedly increased due to an improvement in 
patient survival; an ageing population; the tendency to use pro-
gressively higher doses of anthracyclines; the introduction of new 
anticancer drugs with unexpected cardiac toxicity; and combined 
treatments with synergistic harmful effects on the heart.(2,3) 
According to American cardiologic guidelines, patients receiving 
anticancer treatment may at present be considered a Stage A heart 
failure group, namely those with an increased risk of developing 
LVD.(4) Avoiding cardiotoxicity has therefore become a primary 
Cardiac toxicity induced by anticancer therapy is of con-
siderable concern for, once it develops, it may compromise 
the clinical effectiveness of treatment independent of the 
oncologic prognosis. The main strategy to minimize cardio-
toxicity is to detect high-risk patients and begin prophylactic 
treatment as early as possible. According to the current 
standard for monitoring cardiac function cardiotoxicity is 
usually detected only once a functional impairment has 
already occurred, thus precluding any chance of prevention. 
The measurement of cardio-specifi c biomarkers can be a 
valid diagnostic tool for the early identifi cation, assessment 
and monitoring of cardiotoxicity. 
The role of Troponin I in identifying patients with subclinical 
cardiotoxicity and their subsequent treatment with angio-
tensin-converting enzyme inhibitors to prevent left ventri-
cular ejection fraction (LVEF) reduction and cardiac events, 
is emerging as an effective strategy against these complica-
tions. When this approach is not feasible, a complete LVEF 
recovery and a reduction in cardiac events may be achieved 
if left ventricular dysfunction (LVD) is detected early and 
the patient promptly treated with angiotensin-converting 
enzyme inhibitors, possibly in combination with beta-blocking 

















change in LVEF occurs before the compensatory mechanisms are 
exhausted. 
Once LVD develops, complete recovery of cardiac function occurs 
in only 42% of patients, despite optimal pharmacologic therapy.(6) 
The diagnosis of cardiotoxicity evidenced by a decrease in LVEF 
therefore precludes any chance of preventing its development.(5,7-9) 
Measuring LVEF also presents a number of challenges with regards 
to image quality, assumption of left ventricular geometry, load 
dependency and expertise.(10) Improved accuracy and reproducibility 
of LVEF measurements is an actual need in patients receiving 
anticancer therapy, since clinical decision making relies completely 
on these measurements. Multiple gated acquisition (MUGA) scan 
can reduce inter-observer variability with the disadvantages of 
including the exposure to radioactivity and limited information that 
can be obtained on cardiac structure and diastolic function. 
Magnetic resonance imaging (MRI) is considered the gold standard 
for the evaluation of cardiac volumes, mass, and both systolic and 
diastolic function.(5) However, high cost and the lack of availability 
limit the routine use of MRI. 
These limitations have prompted investigations into the develop-
ment of more sophisticated echocardiographic techniques, like 
contrast echocardiography and real-time 3D-echocardiography, 
which allow for an improvement in the accuracy of calculating 
LVEF.(10,11) Both Doppler tissue imaging and speckle-tracking 
echocardiography appear to be more sensitive than standard 
echocardiography in detecting subclinical changes in cardiac 
performance that anticipate a decrease in conventional LVEF, even 
if long-term data on large populations, confirming the clinical 
relevance of such changes, are not available yet.(10,11)
The role of biomarkers 
A novel approach based on the use of cardiac biomarkers has 
emerged in the last decade, resulting in a cost-effective diagnostic 
tool for early, real time identification, assessment and monitoring of 
anticancer drug-induced cardiotoxicity. This approach seems to 
overcome most of the limitations of the techniques described 
above, as it has proven to be more sensitive and more specific, 
cheaper, repeatable without damage for the patients, readily 
available even in small hospitals, and without inter-observer 
variability.
Troponins
Troponin (Tn) is considered the gold standard biomarker for 
myocardial injury from any cause.(12) The employment of cardiac 
troponins as biomarkers of early chemotherapy-induced cardio-
toxicity was initially reported in animal models.(13) Moving to the 
clinical field, Lipshultz, et al.(14) reported that, in children treated 
with anthracyclines (AC) for lymphoblastic leukaemia, a TnT 
increase in about 30% of cases, sometimes persisting for months, 
suggesting that cardiac damage, elicited by AC, may last for a long 
time. This increase positively correlated with AC dose and predicted 
morbidity and mortality. 
More recently, in the same population, followed-up for 5 years 
after treatment, the authors observed that children who had 
experienced at least one raise in TnT during treatment showed late 
cardiac abnormalities at echocardiography.(15) Further studies have 
demonstrated that TnI is also a sensitive and specific marker for 
myocardial injury in adults treated with high-dose chemotherapy 
(CT), and is able to predict, at a very early phase, both development 
and severity of future LVD (Figure 1).(16-18) Additionally, in 703 
FIGURE 1: Panel A. Left ventricular ejection fraction (LVEF) at 
base-line and during the 7-month follow-up in Troponin I positive 
(TnI pos) and negative (TnI neg) patients. * = p<0.001 vs. baseline 
(month 0); # = p<0.001 vs. TnI neg group. 
Panel B. Scatterplot of LVEF changes against Troponin I value in 
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TABLE 1: Major adverse cardiac events in the overall study population 
and in patients with elevated or normal Troponin I value. (Modified from 
Cardinale, et al.(23))
LVEF = left ventricular ejection fraction. *P <0.001 vs. elevated Troponin I 
(by Fisher exact test).
 Total Elevated Normal  
  Troponin I Troponin I 
 (n=251) (n=36) (n=215)
Severe LVEF reduction (≤30%), n (%) 7 (3) 6 (17) 1 (0.5)
Cardiac death, n (%) 0 (0) 0 (0) 0 (0)
Acute coronary syndrome, n (%) 2 (1) 2 (5) 0 (0)
Acute pulmonary oedema, n (%) 1 (0.5) 1 (3) 0 (0)
Heart failure, n (%) 7 (3) 7 (19) 0 (0)
Arrhythmias requiring treatment, n (%) 5 (2) 2 (8) 3 (1.4)
Cumulative events 22 (9%) 18 (50%) 4 (2%)*
TABLE 2: Elevation of cardiac troponins in patients without overt 
ischaemic heart disease (Modified from Panteghini M.(26)). 
Acute rheumatic fever 
Amyloidosis
Cardiac trauma (including contusion, ablation, pacing, fi ring, cardioversion, 
catheterisation, cardiac surgery)




Glycogen storage disease type II (Pompe’s disease)
Heart transplantation
Haemoglobinopathy with transfusion haemosiderosis
Hypertension, including gestational 







BIOMARKERS: DETECTION AND TREATMENT OF CARDIOTOXICITY
cancer drugs. The role of Troponin I was assessed in 251 breast 
cancer patients treated with trastuzumab.(23) TnI was measured 
immediately before and immediately after each cycle, and resulted 
as having increased in 34 (14%) of patients. LVD occurred in 62% 
of patients showing an increase of TnI during trastuzumab treat-
ment, and in only 5% of those with normal TnI value (p<0.001). 
Patients showing an increase of TnI during trastuzumab treatment 
had a three-fold lower chance of recovery from cardiac dysfunction 
and had a higher incidence of cardiac events (Table 1). In this study, 
therefore, TnI was able to accurately identify patients at risk of 
developing LVD and, among them, those who will less likely recover 
cancer patients, in whom TnI was determined before CT, during 
the following three days after the end of CT (early evaluation) and 
after one month (late evaluation), three different troponin release 
patterns identified patients at different risk of cardiotoxicity. 
Troponin I was consistently negative in 70% of cases, positive at 
only early evaluation in 21%, and positive at both early and late 
evaluations in 9% (Figure 2).(19) During the 3.5 year follow-up, 1%, 
37%, and 84% (p<0.001) of patients, respectively, experienced an 
adverse cardiac event. Thanks to its high negative predictive value 
(99%), TnI allows us to identify low-risk patients who will not 
require further cardiac monitoring. In contrast, TnI positive patients 
require more stringent surveillance, particularly those showing a 
persistent TnI increase. Indeed, these patients experienced a 
greater LVD and a higher incidence of cardiac events than patients 
showing only a transient increase in this marker.(19)
Troponin measurements have proven to be useful for the early 
detection of cardiotoxicity also in patients treated with a standard 
dose of CT. Auner, et al.(20) reported a TnT increase in 15% of 
patients treated with standard doses of AC. Patients with an 
elevated TnT level showed a significantly greater absolute decrease 
in LVEF than those without an elevation in the marker (10% vs. 2%; 
p= 0.017). A significant LVEF reduction was observed in TnI positive 
patients treated with AC for leukemia.(21) In addition, an increased 
TnT level, detected in the first 3-5 days following administration of 
standard doses of AC, predicted diastolic dysfunction in 34% of 
patients.(22)
Troponins may also be utilised for the early detection of cardiac 
injury in patients undergoing treatment with new targeted anti-
FIGURE 2: Early and Late Troponin I (TnI) values in the 3 study 
groups. TnI +/+ (n=63;9%); TnI +/- (n=145;21%); TnI -/- 
(n=495;70%). *=P<0.05 vs. Early TnI; **=P<0.001 vs. Early TnI; 
§=P<0.001 vs. TnI+/-; #=P<0.001 vs. TnI-/-. 



































from cardiotoxicity - despite optimised heart failure treatment - 
thus possibly distinguishing between reversible and irreversible 
cardiac injury. In a recent study, the timing of maximum detectable 
TnI value preceded maximum decline in LVEF in patients receiving 
both trastuzumab and lapatinib - a tyrosine-kinase inhibitor - 
following AC-based CT.(24) In 86 patients with metastatic renal 
cancer treated with tyrosine-kinase inhibitor sunitinib or sorafenib 
and monitored prospectively with serial TnT measurements an 
increase in the markers was observed in 10% of patients. Ninety 
percent of them showed a decrease in LVEF or regional contraction 
abnormalities.(25) These data suggest that troponins may be useful 
for assessing cardiotoxicity in patients treated with both old and 
new antineoplastic treatments. Possibly, the release of troponin 
reflects a final common event for multiple cardiotoxic mechanisms. 
As many non-ischaemic pathophysiological conditions can cause 
myocardial necrosis, and therefore elevations in cardiac troponin 
concentrations (Table 2), other possible causes of troponin increase 
must obviously to be excluded.(26)
Different timing of troponins increase
Following acute ischaemic myocardial damage, troponins show a 
specific kinetic profile: range of times to initial elevation 3-12 hours, 
lasting time up to 7 (TnI) or 14 (TnT) days.(27) On the contrary, the 
time course of troponin changes following CT is more variable and 
less clearly defined. Indeed, data from available studies show that 
troponins changes might be detected at various time intervals after 
CT administration, and are possibly due to different troponin 
release kinetics in response to different treatment schedules con-
taining drugs with possible synergic toxic effect.(14-16,19-23) Moreover, 
the sampling protocols used for measurement of troponins were 
not homogeneous in terms of cut-offs, timing of sampling and 
cardiac endpoints definition. Standardisation of routine troponin 
use in this clinical setting is a current need, and future research 
should focus on the best timing for sampling at which the maximal 
sensitivity and sensibility from a single sample of troponin can be 
obtained. 
Moreover, additional factors may influence the pattern of troponin 
release; these include use of variable cumulative doses of anticancer 
drugs administered, method and timing of administration, and prior 
drugs exposure.(28,29) In breast cancer patients treated with high-
dose AC-containing schedules, we found that the percentage of 
TnI positivity progressively increased in parallel with the increasing 
number of the cycles performed, confirming that the risk of 
cardiotoxicity in AC-treated patients is dose dependent (Figure 3; 
panel A).(17) Conversely, in breast cancer patients treated with 
trastuzumab, we found that the first increase in troponin was most 
frequent soon after the first cycle of trastuzumab and occurred only 
in patients previously treated with AC (Figure 3; panel B), suggesting 
a possible combined mechanism: TnI rise in these patients possibly 
reflects AC injury facilitated by trastuzumab, rather than a de-novo 
cardiac damage.(23) This hypothesis might explain the different 
timing of the rise in TnI in our studies. Many studies have also 
elucidated that troponin value can remain elevated for a period 
ranging from a few hours to several months, after the completion 
of CT.(19,20,21,28,30) On the other hand, the exact time-point at which 
a negative troponin value reaches 100% of specificity for no further 
troponin release cannot yet be defined,(31) therefore, repeated 
blood samples are required to pick out a possible troponin increase. 
This represents a possible limitation for using these markers in 
clinical practice. However, this strategy seems to be justified and 
absolutely cost-effective when negative values allow for the 
exclusion of most patients from a long-term monitoring programme 
with an expensive imaging technique. 
FIGURE 3: Panel A. Time of the fi rst detection of elevated 
troponin value in patients treated with high-dose anthra-
cycline (AC).
Panel B. In patients treated with trastuzumab (TRZ) preceded by 
















































Recently the technological evolution led to the generation of 
troponin assays with improved sensitivity, enabling a reliable 
detection of very low amounts of troponin. These assays are 
referred as “high sensitivity” troponins although definite criteria to 
define their analytical performance are still lacking. These tests 
could be of particular interest in the cardiotoxicity field, and may 
offer some advantages, as often we are dealing with a very low 
concentration of troponin, and it is of utmost importance to use 
systems showing high precision also at a very low level.(32)
The possible employment of high-sensitivity (HS) troponins in this 
setting is provided by a recent multicentre study, in which the 
authors evaluated global and regional myocardial function by tissue 
Doppler and strain rate imaging, combined with HS TnI, at baseline, 
and 3 and 6 months during CT including AC and trastuzumab.(33) 
HS TnI increased in 28% of patients. The decrease in left ventricular 
longitudinal strain, and a detectable HS TnI, at 3 months were 
independent predictors of the development of cardiotoxicity at 
6 months. On the other hand, changes in LVEF, diastolic function, 
and N-terminal pro-Brain Natriuretic Peptide (NT-proBNP), 
evaluated at the same time points, were not predictive of later 
LVD. Further larger investigations comparing HS Tn with tradi-
tional troponin assays are needed.
Natriuretic peptides
During the last 10 years several studies have assessed the clinical 
utility of natriuretic peptides (NP) in the diagnosis and risk assess-
ment of patients with heart failure. Many studies have also 
investigated their possible role for the diagnosis and prediction of 
cardiotoxicity induced by anticancer drugs. The first observation, 
by Suzuky, et al.,(34) dates back to the end of the nineties: a per-
sistent elevation of Brain Natriuretic Peptide (BNP) following AC 
administration was associated with the development of LVD, as 
compared to patients with only transient elevation. Afterwards, 
several papers were published, evaluating a total of more than 
1 200 patients, with different malignancy (haematologic and solid 
tumours), age (children and adults) and oncologic treatment 
(Table 3).(35-55) In most of the studies an association between 
increased levels of NP and LVD was found. However, only few 
reports indicated NP as predictors of LVD after anticancer 
treatment. We conducted a retrospective study including 52 
patients receiving high-dose chemotherapy for aggressive malig-
nancies.(39) Three distinct increase patterns were found, according 
to the NT-proBNP trend during the 6 blood samples taken in the 
72 hours after CT (Figure 4; panel A). Patients who did not mani-
fest significant echocardiographic changes recorded during follow-
up were those who maintained low levels of NT-proBNP for all 
the time of sampling (Group A, 32% of patients) or had only a 
transient increase (Group B, 36% of patients). In patients in whom 
the level of NT-proBNP increased and remained elevated after 72 
hours (Group C, 32% of patients), we observed a deterioration of 
diastolic indexes (mitral deceleration time, isovolumetric relaxation 
time, and mitral E/A ratio) and a decrease in LVEF (from 62.8% to 
45.6; p<0.001) (Figure 4; panel B), in the following months after 
the completion of CT. A strong relationship between NT-proBNP 
value at 72 hours and LVEF changes at 12 months versus baseline 
(r = 0.78; p<0.001) was found. These results are consistent with 
more recent reports in which a NT-proBNP increase during AC-
containing regimens predicted both significant LVD decline and 
overt HF in adults and paediatric populations.(51-55) However, the 
heterogeneousness of data (different populations, sample sizes, 
kind of NP used, method of measurement, cut-offs, cardiac end-
points, duration of follow-up) makes the comparison of the results 
from the different studies quite difficult, and it does not allow us to 
draw definite conclusions or indications regarding the appropriate 
use of these biomarkers in clinical practice.
Other proposed biomarkers
Other molecules have been proposed as biomarkers for cardio-
vascular injury related to CT-induced toxic effect. 
New markers of myocardial ischaemia and necrosis such as fatty 
acid binding protein and glycogen phosphorylase isoenzyme BB 
(brain) have been reported to also increase after CT with AC.(56,57) 
However, although these markers are highly sensitive, they have 
relatively low cardiac specificity and available data are insufficient 
to propose their use in the follow-up of oncology patients.
The increase of markers of inflammation, such as cytokines, has also 
been described after CT. Mercuro, et al.(58) reported a correlation 
between interleukine-6 (IL-6) increase and early changes in systolic 
function when analysed by tissue Doppler imaging in a small 
population of patients treated with CT containing epirubicin. More 
recently the same group showed that the angiotensin II receptor 
blocker telmisartan can reduce AC-induced radical species, 
antagonise the inflammation, and reverse the early myocardial 
impairment.(59) These preliminary results warrant confirmation by 
further, larger prospective investigations. 
Because chemotherapeutic agents can induce endothelial activation, 
several studies have analysed a possible role of molecules deriving 
from endothelial damage as markers of cardiovascular toxicity. 
Nuver, et al.(60) reported an increased level of endothelial dys-
function markers (tissue-type plasminogen activator and plas-
minogen activator inhibitor type I) in patients treated with cisplatin-
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based CT for testicular cancer many years before. In a similar 
population Vaughn, et al.(61) reported that long-term cancer 
survivors treated with CT showed increased markers of endothelial 
injury compared to CT-naive survivors. These findings suggest that 
CT may induce endothelial dysfunction and accelerate athero-
sclerotic processes, leading to an increased risk for future 
cardiovascular diseases.(62) However, at present, no correlation with 
long-term cardiovascular events has been demonstrated, and the 
predictive role of these markers has yet to be defined.
PREVENTION OF CARDIOTOXICITY
Current possible strategies
To prevent cardiotoxicity, several preventive measures are currently 
used, including limitation of cumulative AC dose, slowing down of 
AC administration, and use of less cardiotoxic AC analogues. 
However, the addition of cardioprotectants or nutritional supple-
ments and detection of early signs of cardiotoxicity by biomarkers 
are the two most promising strategies.(11,63,64) 
Addition of cardioprotectants to AC treatment
Carvedilol, a beta-blocker with alfa-1-blocking vasodilatory prop-
erties, has also showed strong antioxidant activity that lends it a 
cardioprotective effect against doxorubicin.(63) This favourable 
effect was confirmed in an in-vitro study(65) and in a randomised 
study in which prophylactic use of carvedilol prevented LVD and 
reduced mortality in a small population of patients treated with 
AC.(66)
Dexrazoxane, an iron-chelating agent, significantly reduced AC-
related cardiotoxicity in adults with different solid tumours and 
in children with acute lymphoblastic leukaemia and Ewing’s 
sarcoma.(15,67,68) Moreover, the same agent was more effective 
than an AC prolonged infusion in preventing cardiotoxicity in 23 
Ewing’s sarcoma patients treated with doxorubicin.(69) Neverthe-
less, dexrazoxane is not routinely used in clinical practice and it is 
recommended as a cardioprotectant by the American Society of 
Clinical Oncology only in patients with metastatic breast cancer 
who have already received more than 300mg/m2 of doxorubicin. 
This might be explained by the suspicion of interference with 
antitumor efficacy of AC and facilitation of the occurrence of 
secondary malignancies as well as by its possible myelosuppressor 
effect. However, meta-analyses didn’t find a significant difference in 
terms of antitumor efficacy and of occurrence of secondary 
malignancies between patients who were treated with and without 
dexrazoxane.(63,67,70,71)
Many other chemical agents have been evaluated such as coenzyme 
Q10, carnitine, N-acetylcysteine, the antioxidant vitamins E and C, 
erythropoietin, the endothelin-1 receptor antagonist bosentan, the 
lipid-lowering agents probucol and statins and some of them 
showed promising results. Other iron-chelating agents, such as 
desferoxamine and EDTA, are also of interest (Table 4). Although 
preliminary findings show that all these agents may have 
cardioprotective effects their utility in preventing CMP need to be 
confirmed by further investigation.(3,11,63,67)
The role of biomarkers in the prevention of cardiotoxicity
A pharmacologic preventive approach extended to all cancer 
patients treated with CT has a high cost-benefit ratio and exposes 
patients to possible side effects, including a potential antagonistic 
effect to antitumor activity of the treatment also in patients less 
FIGURE 4: Panel A. NT-proBNP concentrations at the different 
sampling times. The curve shows 3 patterns according to the 
different behaviour of NT-proBNP. 
Panel B. Left ventricular ejection fraction trend in the 3 study 
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prone to develop cardiotoxicity. A preventive therapy in selected 
high-risk patients only, identified by an increase in cardiac biomarkers 
during and/or after CT, may represent a reasonable alternative. The 
possibility of identifying patients at high-risk of developing cardio-
toxicity by cardiac biomarkers provides a rationale for the 
development of tailored preventive strategies directed at reducing 
the clinical impact of cardiotoxicity. Two different strategies could 
be carried out:
 ■ Use of specific cardiologic treatments given to cancer patients 
during the oncologic treatment in the attempt to prevent or 
blunt the rise of these markers or interfere with their persistence 
after first increase; 
 ■ Use of cardiologic treatments given only to selected cancer 
patients identified by an increase in these markers during CT. 
A recent prospective study reported that valsartan, an angiotensin 
II receptor blocker, given at the same time as doxorubicin was 
able to prevent an increase in atrial natriuretic peptide, BNP, and 
left ventricular diastolic diameter and prolongation and dispersion 
in QTc interval in patients with non-Hodgkin’s lymphoma.(72) 
Lipshultz, et al.(68) reported that TnT elevation occurred significantly 
more frequently in leukaemic children receiving doxorubicin alone 
than in those in whose doxorubicin was administered in association 
with dexrazoxane (50% vs. 21%, respectively; p<0.001).
The usefulness of TnI screening for a selection of patients requiring 
prophylactic cardioprotective therapy was investigated in a rando-
mised, controlled trial carried out at our institute.(30) The cardio-
protective effects of enalapril were evaluated in 413 patients 
treated with high-dose AC. The 114 (24%) patients showing early 
TnI increase were randomised to enalapril or no treatment. 
Enalapril was initiated 1 month after the completion of CT, titrated 
at the maximal tolerated dose, and continued for 1 year. In the 
enalapril-treated group, LVEF did not change during the follow-up 
period. Conversely, in patients not receiving enalapril a progres-
sive reduction in LVEF and an increase in end-diastolic and end-
systolic volumes were observed (Table 5). Moreover, a significantly 
lower incidence of adverse cardiac events was found in enalapril-
treated patients than in controls at a 1-year follow-up (2% vs.52%; 
p<0.001).(30)
Going from clinical research to the real world we applied this 
strategy to our daily clinical practice. A treatment with enalapril is 
usually started in all patients showing a TnI increase after treatment 
with both old and new anticancer drugs. In more than 1 350 treated 
patients no case of significant reduction in LVEF (below 50%) was 
observed during a mean follow-up of 4.6 years (unpublished data). 
These results confirm that this targeted prophylactic approach can 
be really effective in preventing cardiotoxicity and may be easily and 
safely applied in daily clinical practice.
TABLE 4: Therapies for reducing anthracycline toxicity.
 Agent Class  Mechanism  Study subject
Carvedilol b-Adrenergic antagonist Prevention of free radical formation; prevention of depletion of endogenous antioxidants Humans
Valsartan Angiotensin II receptor blocker Inhibition of Angiotensin II effects Humans
Dexrazoxane Chelating agent Prevention of free radical formation; binding to iron inhibits DNA topoisomerase Humans 
Coenzyme Q10 Dietary supplement Antioxidant Humans 
Carnitine Dietary supplement Antioxidant; transfer of long chain fatty acids into mitochondria Humans 
N-acetylcysteine Mucolytic agent Promotion of endogenous antioxidant synthesis Humans 
Vitamin A, C and E Nutrient Antioxidant Animal model/Humans
Erythropoietin Hormone Apoptosis prevention Animal model
Bosentan Endothelin-1 receptor antagonist Decrease infl ammatory markers (TNF-α) and the expression of apoptotic  Animal model
  signaling proteins 
Probucol Lipid-lowering agent Promotion of endogenous antioxidant synthesis Animal model
Fluvastatin Statin Antioxidant Animal model
Glutathione Tripeptide thiol Antioxidant Animal model
Selenium Trace element Antioxidant; anticarcinogenic action Animal model
Amifostine Cytoprotective agent Antioxidant; scavenges reactive oxygen species Animal model
Desferoxamine Iron-chelating agent Production of reactive oxygen species Animal model
258
The role of biomarkers in clinical trials
Measurement of cardiac biomarkers, and in particular of troponins, 
could allow for an early and objective diagnosis of cardiac toxicity 
in clinical trials evaluating cardiac safety of new antitumoral agents. 
The usefulness of TnI monitoring in patients treated with developing 
molecular targeted therapies has recently been highlighted in phase 
I trials, by Ederhy, et al.(73) Ninety patients with solid metastatic 
tumours were treated with new anti-VEGF monoclonal inhibitors 
and tyrosine kinase inhibitors in a phase 1 trial. All patients were 
also monitored with serial TnI measurement. Ten of them (11%) 
showed an increase in TnI during the cancer treatment. These 
underwent echocardiography, cardiac MR, CT scan, and coronary 
angiography to exclude other possible causes of TnI rise. Nor-
malisation of TnI values was obtained with a treatment associating 
beta-blockers (BB) and aspirin; then all patients were re-challenged 
with the study drug. No patient experienced any new increase of 
TnI, and no cardiac events occurred during the subsequent 
observation period (mean follow-up: 3 months). The authors 
concluded that the use of TnI allows for the early identification of 
patients more prone to develop cardiotoxicity when exposed to a 
new drug in cancer clinical trials. These data suggest that patients 
showing myocardial injury, revealed by the increase in TnI, should 
be treated with a prophylactic therapy in order to prevent overt 
cardiotoxicity and should not be excluded from continuing 
oncologic treatment. Accordingly, the definition of cardiotoxicity in 
cancer clinical trials, still based on the evidence of symptomatic 
heart failure or asymptomatic decrease in LVEF, should be changed 
moving from a late clinical to an early subclinical definition. As a 
result the apparent increase in the incidence of subclinical cardio-
toxicity due to the low threshold of detection of cardiac injury will 
be counterbalanced by a lower incidence of clinical cardiotoxicity 
with a raise in net clinical benefit of the new antitumoral treatment.
TREATMENT OF CARDIOTOXICITY
Anthracyclines-induced cardiotoxicity
Historically, AC-induced cardiomyopathy (CMP) was believed to 
be refractory to conventional therapy. This opinion was however 
based either on findings reported in old studies, in which standard 
therapy included only the use of digoxin and diuretics, or in studies 
with very small sample sizes.(64) The response to modern HF 
therapy of patients with AC-induced CMP has never been fully 
evaluated because these patients have typically been excluded 
from large randomised trials investigating novel HF therapies. As a 
result, the use of angiotensin-converting enzyme inhibitors (ACEI) 
and BB in this particular clinical setting remain a matter of debate. 
Moreover the different etiology and age distribution of this kind 
of CMP when compared with the more frequent ischaemic or 
idiopathic CMPs raise some concern whether the use of ACEI and 
BB - recommended for other forms of CMPs - can be directly 
transferred to this particular clinical setting with similar long-term 
benefits. Finally as LVD due to anticancer drugs is in most cases 
asymptomatic many authors have suggested that screening pro-
grammes should look for overt HF and current management of 
LVD induced by anticancer therapy mainly focuses on treatment of 
symptomatic patients.(74) This is probably due to the fact that there 
are special concerns in using ACEI and BB in such a population 
probably for the fear of unknown pharmacologic interactions. 
Because cancer patients are considered frail the tendency is not to 
treat them aggressively. Hence, evidence-based recommendations 
for the management of cancer patients who develop asymptomatic 
or symptomatic LVD after CT are still lacking.
In a recent study, the response to modern HF therapy, including 
ACEI and BB has been prospectively evaluated in 201 patients with 
AC-induced CMP.(6) In this study the time elapsed from the end of 
CT to the start of HF therapy (time-to-treatment) including ACEI 
TABLE 5: Echocardiographic parameters during the study period (Modified from Cardinale, et al.(30))
  Baseline    Rand. 3 months  6 months  12 months   P value*
EDV (ml)  ACEI-group 101.7 ± 27.4 100.2 ± 26.1  98.1 ± 27.8  97.5 ± 24.5 101.1 ± 26.4 
0.045
 Controls 103.2 ± 20.1 103.9 ± 21.0 106.4 ± 21.0 107.1 ± 23.9 104.2 ± 25.6
ESV (ml)  ACEI-group 38.6 ± 10.8 38.7 ± 10.4 37.3 ± 10.9 37.4 ± 10.3  38.5 ± 11.2 
<0.001
 Controls 38.8 ± 10.2 40.5 ± 12.2 49.8 ± 17.6 51.8 ± 16.9  54.4 ± 20.1#
LVEF (%)  ACEI-group 61.9 ± 2.9 61.1 ± 3.2 61.9 ± 3.3 61.6 ± 3.9  62.4 ± 3.5 
<0.001
 Controls 62.8 ± 3.4 61.8 ± 4.3 54.2 ± 8.1 51.9 ± 7.9  48.3 ± 9.3#
*P value for repeated measures analysis of variance. #p<0.001 vs. baseline. EDV = end-diastolic volume. ESV = end-systolic volume. LVEF = left ventricular ejection fraction Rand. = randomisation. 


















The incorporation of trastuzumab, a monoclonal antibody targeting 
human epidermal growth factor receptor 2, to the standard 
regimens for treatment of breast cancer that over-expresses HER2 
receptors - a variant of the disease generally associated with a poor 
prognosis – has led to a major improvement in outcome.(75) Its use 
however has resulted in an unexpectedly high rate of cardiotoxicity 
which occurs in up to 7% of patients when used as monotherapy 
and in 28% of patients when associated with AC.(1)
Trastuzumab causes a different form of cardiotoxicity from that 
typical of AC: It is not dose-dependent; AC-typical ultra structural 
changes are not seen on cardiac biopsy specimens; and it is not 
caused by oxidative mechanisms.(75) The clinical outcome of patients 
who develop trastuzumab-induced cardiotoxicity seems more 
favourable and cardiac function generally improves after withdrawal 
on removal of the agent and initiation of HF therapy. Treatment of 
trastuzumab-related cardiotoxicity is a still controversial issue. Most 
patients (60-80%) significantly improve their LVD when treated 
with drugs commonly used for HF such as ACEI and BB.(76) As 
patients who developed LVD in the adjuvant trastuzumab trials 
were not treated in a systematic manner the natural history of 
trastuzumab cardiotoxicity is currently unknown and evidence-
based recommendations for its management are still lacking. 
Whether trastuzumab-related LVD has a course that is modified 
with ACEI and BB is still uncertain.(77)
Follow-up data from large trials show that in many patients treated 
with anthracycline and sequentially with trastuzumab LVD does 
and, when tolerated, BB was a critical variable for recovery from 
LVD. Indeed, a strong inverse relationship between time-to-
treatment and LVEF improvement in response to HF therapy was 
observed (R = -0.66; p<0.001). In particular, the likelihood of 
obtaining a complete LVEF recovery was higher in patients in 
whom HF treatment was initiated because of LVD detection within 
2 months after the end of CT. After this time limit the percentage 
of complete LVD recovery progressively decreased and only partial 
recovery was observed after 6 months. When LVD was detected 
after 12 months the possibility of obtaining at least a partial recovery 
was completely exhausted (Figure 5). Notably patients showing 
complete LVD recovery had a significantly lower rate of adverse 
cardiac events than those who did not recover (5% vs. 30%). 
Moreover complete recovery was more frequently observed in 
patients with asymptomatic LVD than in those with symptoms of 
HF (56% vs. 11%; p<0.001).(6) The monitoring of cardiotoxicity 
based exclusively on symptoms evaluation may therefore hinder 
the opportunity to detect LVD early in a still asymptomatic and 
reversible stage. It is also likely that in most previously published 
studies the poor response to HF therapy was due to under-
treatment with ACEI and BB and to late beginning of HF therapy 
(in most cases it was started more than 12 months after the end 
of chemotherapy) when LVD has been shown to be no longer 
reversible. This underlines that an early detection of cardiotoxicity 
is of pivotal importance and that a prompt therapy based on the 
association of ACEI and BB should always be considered and 
undertaken in all cases of anthracycline-induced CMP. 
FIGURE 5: Percentage of patients showing a complete (green bars) or partial (blue bars) left ventricular ejection fraction recovery according to the 
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all survival of cancer patients. The most effective approach to 
minimise cardiotoxicity lays in early detection and prompts 
prophylactic treatment initiation. The role of TnI in identifying 
patients at high-risk of cardiotoxicity and their treatment with 
ACEI is clearly emerging as an effective strategy against this com-
plication (Figure 6). In patients developing LVD after anticancer 
therapy a complete LVEF recovery and a reduction of cardiac 
events may be obtained only when LVD is detected early and a 
treatment with ACEI, possibly in combination with BB, is promptly 
initiated.(79)
Conflict of interest: none declared.
not recover; that up to two-thirds of patients continue to receive 
cardiac medications after complete functional recovery; and that 
many patients show a LVEF lower than baseline despite optimal HF 
therapy.(78) For these reasons some uncertainties on resuming 
trastuzumab after cardiac function recovery still exist. This is 
particularly true for patients treated with curative intent while the 
risk of developing cardiac impairment in the metastatic setting is 
largely counterbalanced by the benefit of trastuzumab. 
CONCLUSION 
At present, anticancer treatment-induced cardiotoxicity still remains 
a serious problem strongly impacting both quality of life and over-
FIGURE 6: Algorithm for the management of cardiotoxicity in patients receiving anthracyclines. ACEI = angiotensin-converting enzyme inhibitors; 
BB = beta-blocking agents. CT= chemotherapy. ECHO = echocardiogram. TnI = Troponin I. LVD = left ventricular dysfunction. Modifi ed from 
Cardinale D. Braunwald Heart Disease E-dition.(79)
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